Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilexs Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a f
June 23, 2025 16:50 ET | Source: Scilex Holding Company PALO ALTO,…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
From IIT to Inner Transformation: Gauranga Das Calls for a Revival of Dharmic Values at IGF London
Spiritual leader Gauranga Das urges a return to purpose-driven living, cultural humility, and…
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic…
SBI Life crowdsources future-facing AI solutions from India’s Next-Gen Talent pool at the 2025 Hack-AI-Thon finale
The initiative underscored SBI Life's focus on innovation, young talent, and building…
IvoryLab fast-tracks development with support from the Telnyx AI Accelerator
AUSTIN, TX, June 19, 2025 (GLOBE NEWSWIRE) -- Telnyx, a leading provider…
AlphaGrep Receives In-Principle Approval from SEBI to Sponsor Mutual Fund
MUMBAI, India, June 19, 2025 /PRNewswire/ -- AlphaGrep Securities, a leading quantitative…
Terra Motors Appoints L5 Dealership to Top L3 Dealers in Varanasi, Offering 200km Range from 3.65 Lakh with Zero Down Payment; Targets 100 Dealers Across India
NEW DELHI, June 18, 2025 /PRNewswire/ -- Terra Motors, a Japanese electric…
GENESIS MAGMA RACING TAKES POSITIVES FROM FIRST 24 HOURS OF LE MANS PARTICIPATION
Genesis Magma Racing drivers and team members took valuable lessons from first…
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
